Uso de plasma convalescente em pacientes com COVID-19

Abstract

This Collective Health doctoral thesis of the Collective Health Graduate Program at the University of Vale do Rio dos Sinos – UNISINOS – aimed to evaluate the prognostic indicators in critically ill patients with SARS-CoV-2 infection, hospitalized in an Intensive Care Unit (ICU) at Virvi Ramos Hospital in Caxias do Sul/RS, treated or not with convalescent plasma for COVID-19 (PCC). In addition, a survival analysis was also performed. This thesis is composed of two articles. The first makes a mini-review on the early use of convalescent plasma for COVID-19 as a potential low-cost treatment for patients in risk groups, especially in countries with little access to antiviral therapies and vaccines. The second article is a retrospective, propensity-matched cohort study of patients hospitalized in the ICU for severe COVID-19 who received PCC transfusion plus standard care, compared with controls who received standard care only. The primary outcome was mortality within 30 days of admission to the ICU. A total of 124 patients (62 in each group) were included. The median age for the entire series was 66 years (IQR: 55-73), and 89 (55.6%) were men. The median time from symptom onset to PCC was 10 days (IQR: 8-13 days). In total, 51 (41.1%) died within 30 days of admission. PCC transfusion was not independently associated with lower 30-day mortality (OR: 0.52, 95% CI: 0.23–1.16; p = 0.11) and also had no impact on mechanical ventilation or same time.